Comparative Pharmacology
Head-to-head clinical analysis: CU 7 versus SELFEMRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CU 7 versus SELFEMRA.
CU-7 vs SELFEMRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The Cu-7 intrauterine device (IUD) releases copper ions, which inhibit sperm motility and viability, and alter the endometrial environment to prevent implantation.
Selective estrogen receptor degrader (SERD) that binds to estrogen receptor alpha (ERα), inducing its degradation and inhibiting estrogen-dependent cell proliferation.
50 mg orally once daily
1 tablet (50 mg) orally once daily with food.
None Documented
None Documented
Not applicable; intrauterine device with no systemic elimination half-life. Copper release is continuous with a rate of approximately 38 µg/day, declining over time.
Terminal elimination half-life of 12-16 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min).
Primarily fecal (80-90%) as unabsorbed copper; negligible renal excretion (<1%).
Primarily renal excretion as unchanged drug (50-60%) and metabolites (20-30%); biliary/fecal elimination accounts for 10-15%.
Category C
Category C
Contraceptive
Contraceptive, Combination Hormonal